Drug Metabolism and Disposition
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al
The Mechanism: Like Botulinum Toxin and Argireline, Snap-8 targets the SNARE complex the cellular machinery required for neurons to release acetylcholine (the chemical that triggers muscle contraction)
All use must remain within research-only boundaries - neither compound is approved by the FDA or EMA, BPC-157 was placed on the FDA 503A Category 2 list in 2023, and TB-500 is on the WADA Prohibited List under class S2
With steady advancement of regulatory approval processes, DPP1 inhibitors are expected to become important treatment options for diseases such as bronchiectasis in the near future